Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Anthony John Iafrate, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Anthony Iafrate and Jochen Lennerz.
Connection Strength

6.183
  1. Health Care Infrastructure for Financially Sustainable Clinical Genomics. J Mol Diagn. 2016 09; 18(5):697-706.
    View in: PubMed
    Score: 0.691
  2. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011 Dec 20; 29(36):4803-10.
    View in: PubMed
    Score: 0.498
  3. Identification of a small and lethal subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib by MET amplification. J Clin Oncol. 2011 May 20; 29(15_suppl):4130.
    View in: PubMed
    Score: 0.482
  4. Remote Fingerstick Blood Collection for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Testing. Arch Pathol Lab Med. 2021 04 01; 145(4):415-418.
    View in: PubMed
    Score: 0.239
  5. High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts. J Infect Dis. 2020 11 13; 222(12):1955-1959.
    View in: PubMed
    Score: 0.233
  6. Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital. FASEB J. 2020 10; 34(10):13877-13884.
    View in: PubMed
    Score: 0.229
  7. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Neuro Oncol. 2019 05 06; 21(5):596-605.
    View in: PubMed
    Score: 0.209
  8. Clinical Validation of a Cell-Free DNA Gene Panel. J Mol Diagn. 2019 07; 21(4):632-645.
    View in: PubMed
    Score: 0.209
  9. Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma. Oncologist. 2019 10; 24(10):1356-1367.
    View in: PubMed
    Score: 0.208
  10. Highly Multiplexed Fluorescence in Situ Hybridization for in Situ Genomics. J Mol Diagn. 2019 05; 21(3):390-407.
    View in: PubMed
    Score: 0.207
  11. Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History. J Thorac Oncol. 2019 05; 14(5):835-843.
    View in: PubMed
    Score: 0.205
  12. Implementing the DICOM Standard for Digital Pathology. J Pathol Inform. 2018; 9:37.
    View in: PubMed
    Score: 0.202
  13. Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.198
  14. Artificial Intelligence Approach for Variant Reporting. JCO Clin Cancer Inform. 2018; 2.
    View in: PubMed
    Score: 0.194
  15. MET Amplification in Esophageal Squamous Carcinoma. Int J Surg Pathol. 2018 12; 26(8):731-732.
    View in: PubMed
    Score: 0.194
  16. Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations. Neuro Oncol. 2017 Nov 29; 19(12):1640-1650.
    View in: PubMed
    Score: 0.190
  17. KIF13B-NRG1 Gene Fusion and KRAS Amplification in a Case of Natural Progression of Lung Cancer. Int J Surg Pathol. 2017 May; 25(3):238-240.
    View in: PubMed
    Score: 0.182
  18. Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer. Int J Colorectal Dis. 2016 05; 31(5):973-982.
    View in: PubMed
    Score: 0.169
  19. t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. Blood Adv. 2021 Sep 29.
    View in: PubMed
    Score: 0.062
  20. Identification of EWSR1-NFATC2 fusion in simple bone cysts. Histopathology. 2021 May; 78(6):849-856.
    View in: PubMed
    Score: 0.060
  21. GPS-estimated foot traffic data and venue selection for COVID-19 serosurveillance studies. medRxiv. 2021 Feb 05.
    View in: PubMed
    Score: 0.059
  22. Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2021 Jun 15; 27(12):3404-3413.
    View in: PubMed
    Score: 0.059
  23. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021 01 21; 184(2):476-488.e11.
    View in: PubMed
    Score: 0.059
  24. COVID-19 neutralizing antibodies predict disease severity and survival. medRxiv. 2020 Oct 20.
    View in: PubMed
    Score: 0.058
  25. Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers. Oncologist. 2020 11; 25(11):e1691-e1700.
    View in: PubMed
    Score: 0.058
  26. Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. Nat Biotechnol. 2020 10; 38(10):1174-1183.
    View in: PubMed
    Score: 0.057
  27. Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2020 09 15; 26(18):4852-4862.
    View in: PubMed
    Score: 0.057
  28. Test performance evaluation of SARS-CoV-2 serological assays. medRxiv. 2020 May 17.
    View in: PubMed
    Score: 0.056
  29. Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC. J Thorac Oncol. 2020 09; 15(9):1497-1506.
    View in: PubMed
    Score: 0.056
  30. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clin Cancer Res. 2020 04 15; 26(8):1877-1885.
    View in: PubMed
    Score: 0.055
  31. Novel and established EWSR1 gene fusions and associations identified by next-generation sequencing and fluorescence in-situ hybridization. Hum Pathol. 2019 11; 93:65-73.
    View in: PubMed
    Score: 0.053
  32. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discov. 2019 08; 9(8):1064-1079.
    View in: PubMed
    Score: 0.052
  33. Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. Hum Pathol. 2019 04; 86:1-11.
    View in: PubMed
    Score: 0.051
  34. Enrichment of HER2 Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. Oncologist. 2019 02; 24(2):193-201.
    View in: PubMed
    Score: 0.051
  35. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discov. 2018 12; 8(12):1529-1539.
    View in: PubMed
    Score: 0.050
  36. Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. Clin Cancer Res. 2019 01 01; 25(1):158-165.
    View in: PubMed
    Score: 0.050
  37. Genotype-targeted local therapy of glioma. Proc Natl Acad Sci U S A. 2018 09 04; 115(36):E8388-E8394.
    View in: PubMed
    Score: 0.050
  38. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.050
  39. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018 06; 8(6):714-729.
    View in: PubMed
    Score: 0.049
  40. Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.048
  41. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 05; 12(5):872-877.
    View in: PubMed
    Score: 0.045
  42. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov. 2017 03; 7(3):252-263.
    View in: PubMed
    Score: 0.044
  43. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016 10; 6(10):1118-1133.
    View in: PubMed
    Score: 0.043
  44. Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival. Genes Chromosomes Cancer. 2016 08; 55(8):626-39.
    View in: PubMed
    Score: 0.043
  45. Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. Cancer Discov. 2015 12; 5(12):1271-81.
    View in: PubMed
    Score: 0.041
  46. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One. 2011 Mar 29; 6(3):e17948.
    View in: PubMed
    Score: 0.030
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.